Apogee Therapeutics Inc. loaded up on what could total as much as $1.3 billion in financial fuel from Blackstone Life Sciences funds that will be used to propel zumilokibart (zumi), which yielded positive phase II results in atopic dermatitis (AD). A phase III experiment with the anti-IL-13 antibody is planned for the second half of this year, pending talks with regulators. Read More
On the heels of the multibillion-dollar licensing deal between Bristol Myers Squibb Co. and Jiangsu Hengrui Pharmaceuticals Co. Ltd., Chairman John Moolenaar (R-MI), of the House Select Committee on the Chinese Communist Party, sent a letter to Treasury Secretary Scott Bessent urging him to add biotechnology as a prohibited technology under the Comprehensive Outbound Investment National Security (COINS) Act of 2025. Read More
D&D Pharmatech Inc. announced May 27 positive top-line tissue biopsy results of zabopegdutide (DD-01) from a 48-week phase II study of metabolic dysfunction-associated steatohepatitis (MASH), pushing company shares up 30% on the day. Read More
There are initial signs that President Donald Trump’s most-favored nation (MFN) policy may be further delaying access to new drugs in Europe, as companies hold off commercializing in these countries to avoid lower European prices being referenced in the U.S. Read More
The “deep dive” April 8 by Ovid Therapeutics Inc. into potassium-chloride co-transporter 2 (KCC2) research included company officials and independent experts in the space, where a handful of drug developers are known to be working. New York-based Ovid owns a portfolio of potential first-in-class direct activators of KCC2, and the firm detailed pharmacodynamic results along with the translational and clinical development strategy. Read More
Insulet Corp. has initiated a voluntary medical device correction affecting insulin pump pods in its Omnipod product lines after discovering a manufacturing issue that could lead to the leaking of insulin and the under-delivery of doses in some patients. The company said that some pods from specific lots may have a small tear in the cannula. Read More
Biopharma and med-tech companies raising money in public or private financings, including: Biostem, Cartesian, Editas, Hanchorbio, Kane, Mindmaze, Nanobiotix, Rani. Read More
Clinical updates for biopharma and med tech, including data readouts and publications: Abivax, Biohaven, Bionano, Corbus, Eli Lilly, Gain, Genprex, Hologic, Kura, LIB, Nervgen, Renovorx, Sun, Virax. Read More
Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: 28bio, Adcedno, Aim Medical, Biocytogen, Biomunex, Bioprotect, Cgbio, Co-Diagnostics, Cosara, Depuy, Dexcom, Gordion, Human Life Foundation Models, Human Longevity, Insilico, Jiangxi Kvvit, Merck, Merz, Minmaxmedical, Olympus, Oncopeptides, Saga, Salus, Siemens, Tangramed, Vialase. Read More
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Autobahn, Cornerstone, Dyne, Gilead, H. Lundbeck, Microbot, Outlook, Pfizer, Pharming, Spectral, Toby. Read More
